The acquisition — the industry’s largest since 2019 — would give Pfizer control of a top-selling lymphoma drug and a pipeline of medicines that have propelled the Seattle-based company to become one of the sector’s most valuable biotechs.
The acquisition — the industry’s largest since 2019 — would give Pfizer control of a top-selling lymphoma drug and a pipeline of medicines that have propelled the Seattle-based company to become one of the sector’s most valuable biotechs.
Copyright © 2023 Biotech Networks, LLC